암면역치료 연관 내분비 이상반응 = Cancer Immunotherapy Related Endocrine Adverse Effects

다국어 초록 (Multilingual Abstract)

Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) monoclonal antibodies have proven to be especially effective in various advanced cancers. However, cancer the immunotherapy disturbs the immune system and may also cause immune related side effects (IRAE) distinguished from cytotoxic chemotherapy toxicity. Among them, endocrine IRAE has been reported with a higher incidence than other organ IRAE. We focus on the most relevant and new aspects related to endocrine IRAE due to cancer immunotherapy in this review.

참고문헌 (Reference)

1 Chalan P, "Thyroid dysfunctions secondary to cancer immunotherapy" 41 (41): 625-638, 2018

2 Morganstein DL, "Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma" 86 (86): 614-620, 2017

3 Abu-Sbeih H, "The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes" 1 (1): 7-18, 2018

4 Laurent S, "The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production" 11 : 108-, 2013

5 Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer" 366 (366): 2443-2454, 2012

6 Bellastella G, "Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects" 19 (19): 625-642, 2016

7 Hughes J, "Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy" 38 (38): e55-e57, 2015

8 Iwama S, "Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody" 6 (6): 230-245, 2014

9 Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma" 372 (372): 2521-2532, 2015

10 Weber JS, "Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma" 119 (119): 1675-1682, 2013

11 Faje AT, "Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma" 99 (99): 4078-4085, 2014

12 Min L, "Ipilimumab-induced autoimmune adrenalitis" 1 (1): e15-, 2013

13 Marlier J, "Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports" 47 (47): 878-883, 2014

14 Orlov S, "Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies" 100 (100): 1738-1741, 2015

15 de Filette J, "Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab" 101 (101): 4431-4439, 2016

16 Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma" 363 (363): 711-723, 2010

17 Ricciuti B, "Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multiinstitutional analysis" 145 (145): 479-485, 2019

18 Iyer PC, "Immune-related thyroiditis with immune checkpoint inhibitors" 28 (28): 1243-1251, 2018

19 Horvat TZ, "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center" 33 (33): 3193-3198, 2015

20 Michot JM, "Immune-related adverse events with immune checkpoint blockade: a comprehensive review" 54 : 139-148, 2016

21 Indini A, "Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma" 145 (145): 511-521, 2019

22 Joshi MN, "Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review" 85 (85): 331-339, 2016

23 Lowe JR, "Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy" 4 : 89-, 2016

24 Soularue E, "Enterocolitis due to immune checkpoint inhibitors: a systematic review" 67 (67): 2056-2067, 2018

25 Ryder M, "Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution" 21 (21): 371-381, 2014

26 Corsello SM, "Endocrine side effects induced by immune checkpoint inhibitors" 98 (98): 1361-1375, 2013

27 Ruggeri RM, "Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)" 42 (42): 745-756, 2019

28 Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma" 373 (373): 23-34, 2015

29 Guaraldi F, "Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution" 41 (41): 549-556, 2018

30 Iglesias P, "Cancer immunotherapy-induced endocrinopathies:clinical behavior and therapeutic approach" 47 : 6-13, 2018

31 Ott PA, "CTLA-4 and PD-1/PD-L1blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients" 19 (19): 5300-5309, 2013

32 Martin-Liberal J, "Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report" 64 (64): 765-767, 2015

33 Gaudy C, "Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes" 38 (38): e182-e183, 2015

34 Mellati M, "Anti-PD-1 and Anti-PDL-1monoclonal antibodies causing type 1 diabetes" 38 (38): e137-e138, 2015

35 Dillard T, "Anti-CTLA-4antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes" 13 (13): 29-38, 2010

36 Win MA, "Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism" 35 (35): 1039-, 2017

37 Howard SA, "A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy" 207 (207): 4-14, 2016

38 Chae YK, "A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1diabetes" 66 (66): 25-32, 2017